Jose Lutzky is an Oncology physician affiliated with University of Miami. OpenAlex indexes 219 publications with 25,961 citations (h-index 47); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 14th Ave
Miami, FL 331251616
Telephone
305-689-6500Provider last certified this registry record 17 Sept 2022.
Clinical trials
- Adjuvant Quisinostat in High-Risk Uveal Melanoma
Sponsor: University of Miami
- Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Sponsor: Jose Lutzky, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Immunocore LimitedProgram year20258 payments
- Iovance Biotherapeutics, Inc.Program year20254 payments
- Janssen Scientific Affairs, LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.8%Mitogen-activated protein kinase (MEK) inhibitors24.3%Mektovi100%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors23.5%Braftovi100%Part D<11 patientsHormonal (systemic)
25.7%l-Thyroxine25.7%Levothyroxine Sodium100%Part D≥17 patientsMetabolism & gastrointestinal
17.3%Corticosteroid9.3%Prednisone100%Part D<11 patientsProton pump inhibitor8%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Jay Spiegel, MD
University of Miami
Kara Cavuoto, MD
University of Miami
Sixto Arias, MD
University of Miami
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”